Kanai T, Konno H, Maruyama K, Baba M, Tanaka T, Maruo Y, Nishino N, Nakamura S, Baba S, Sugimura H
Second Department of Surgery, Hamamatsu University School of Medicine, Japan.
Eur Surg Res. 1997;29(1):35-41. doi: 10.1159/000129505.
We investigated p53 overexpression and the proliferative activity of the primary lesion as well as the clinicopathological features of 75 patients with gastric cancer invading the submucosa (sm cancer), of whom 14 (18.7%) had lymph node metastasis. Among the clinicopathologic features studied, only lymphatic invasion by the primary tumor was related to lymph node metastasis. There was no relationship between immunohistochemical staining for p53 protein or Ki-67 and lymph node metastasis. The p53-positive rate was 35.7 and 57.1% in patients with and without metastasis, respectively, while the mean Ki-67 labeling index was 38.9 and 38.1%, respectively. Our results suggest that p53 mutation or the proliferative activity of sm cancer do not influence lymph node metastasis, even though p53 mutation may enhance the proliferative activity and metastatic potential of advanced gastric cancer.
我们研究了75例侵犯黏膜下层的胃癌（sm癌）患者的p53过表达、原发灶的增殖活性以及临床病理特征，其中14例（18.7%）发生了淋巴结转移。在所研究的临床病理特征中，仅原发肿瘤的淋巴管侵犯与淋巴结转移有关。p53蛋白或Ki-67的免疫组化染色与淋巴结转移之间无相关性。有转移和无转移患者的p53阳性率分别为35.7%和57.1%，而平均Ki-67标记指数分别为38.9%和38.1%。我们的结果表明，sm癌的p53突变或增殖活性并不影响淋巴结转移，尽管p53突变可能增强进展期胃癌的增殖活性和转移潜能。
